1 patent currently held
176 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next US patent term in the Twenty Twenty Therapeutics LLC portfolio ends in Jun 2040. from the record
Of the 176 now held by other companies, 159 name Verily Health Inc. as their current owner, and 17 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jun 2040
Next term end
1
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
None of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Sep 2032 · Low confidence
Cited by 65 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.
now held by Verily Health Inc.
Also notable
Ends Apr 2030 · High confidence
Cited by 60 later US patents, top 10% of design patents granted in 2016 in our data. Protection runs to 2030.
now held by Verily Health Inc.
Also notable
Ends May 2035 · High confidence
Cited by 30 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
now held by Verily Health Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jul 16, 2027The maintenance fee for Natural Physio-Optical User Interface for Intraocular Microdisplay (US 11,874,462) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
Recent changes
- 10 of the patents on this record were granted since Aug 24, 2026
- 1 term has ended since Aug 24, 2026
- Oct 9 US 10,092,397 Infrared Communication with an Opthalmic Device · lapsed on the fee record
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Natural Physio-Optical User Interface for Intraocular Microdisplay | 1 in force | to Jun 2040 |
Patents held now
Soonest term end first.
Showing 1 to 1 of 1
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,874,462 | Natural Physio-Optical User Interface for Intraocular Microdisplay In force · High confidence | In force | High confidence |
Also on record, not counted in the 1: 176 patents in force now held by others · 3 patents ended · 42 applications pending · 20 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed
10 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.